Increased selenoprotein P levels in subjects with visceral obesity and nonalcoholic fatty liver disease

Hae Yoon Choi, Soon Young Hwang, Chang-Hee Lee, Ho Cheol Hong, Sae Jeong Yang, Hye-Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei-Hyun Baik, Dong Seop Choi, Kyung Mook Choi

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Selenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP, visceral obesity, and nonalcoholic fatty liver disease (NAFLD). Methods: We examined serum SeP concentrations in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography. Our study subjects included 120 nondiabetic individuals selected from participants of the Korean Sarcopenic Obesity Study. In addition, we evaluated the relationship between SeP and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hsCRP), adiponectin values, and brachial-ankle pulse wave velocity (baPWV). Results: Subjects with NAFLD showed increased levels of HOMA-IR, hsCRP, VFA, and several components of metabolic syndrome and decreased levels of adiponectin and high density lipoprotein cholesterol than those of controls. Serum SeP levels were positively correlated with VFA, hsCRP, and baPWV and negatively correlated with the liver attenuation index. Not only subjects with visceral obesity but also those with NAFLD exhibited significantly increased SeP levels (P<0.001). In multiple logistic regression analysis, the subjects in the highest SeP tertile showed a higher risk for NAFLD than those in the lowest SeP tertile, even after adjusting for potential confounding factors (odds ratio, 7.48; 95% confidence interval, 1.72 to 32.60; P=0.007). Conclusion: Circulating SeP levels were increased in subjects with NAFLD as well as in those with visceral obesity and may be a novel biomarker for NAFLD.

Original languageEnglish
Pages (from-to)63-71
Number of pages9
JournalDiabetes and Metabolism Journal
Volume37
Issue number1
DOIs
Publication statusPublished - 2013 Feb 1

Fingerprint

Selenoprotein P
Abdominal Obesity
Intra-Abdominal Fat
C-Reactive Protein
Insulin Resistance
Pulse Wave Analysis
Adiponectin
Ankle
Arm
Homeostasis
Non-alcoholic Fatty Liver Disease
Liver
Serum
HDL Cholesterol
Energy Metabolism
Rodentia
Obesity
Biomarkers
Logistic Models
Fats

Keywords

  • Hepatokine
  • Insulin resistance
  • Non-alcoholic fatty liver disease
  • Obesity
  • Selenoprotein P

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Increased selenoprotein P levels in subjects with visceral obesity and nonalcoholic fatty liver disease. / Choi, Hae Yoon; Hwang, Soon Young; Lee, Chang-Hee; Hong, Ho Cheol; Yang, Sae Jeong; Yoo, Hye-Jin; Seo, Ji A; Kim, Sin Gon; Kim, Nan Hee; Baik, Sei-Hyun; Choi, Dong Seop; Choi, Kyung Mook.

In: Diabetes and Metabolism Journal, Vol. 37, No. 1, 01.02.2013, p. 63-71.

Research output: Contribution to journalArticle

@article{e78ee6c1b0b448a5979647b45750a081,
title = "Increased selenoprotein P levels in subjects with visceral obesity and nonalcoholic fatty liver disease",
abstract = "Background: Selenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP, visceral obesity, and nonalcoholic fatty liver disease (NAFLD). Methods: We examined serum SeP concentrations in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography. Our study subjects included 120 nondiabetic individuals selected from participants of the Korean Sarcopenic Obesity Study. In addition, we evaluated the relationship between SeP and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hsCRP), adiponectin values, and brachial-ankle pulse wave velocity (baPWV). Results: Subjects with NAFLD showed increased levels of HOMA-IR, hsCRP, VFA, and several components of metabolic syndrome and decreased levels of adiponectin and high density lipoprotein cholesterol than those of controls. Serum SeP levels were positively correlated with VFA, hsCRP, and baPWV and negatively correlated with the liver attenuation index. Not only subjects with visceral obesity but also those with NAFLD exhibited significantly increased SeP levels (P<0.001). In multiple logistic regression analysis, the subjects in the highest SeP tertile showed a higher risk for NAFLD than those in the lowest SeP tertile, even after adjusting for potential confounding factors (odds ratio, 7.48; 95{\%} confidence interval, 1.72 to 32.60; P=0.007). Conclusion: Circulating SeP levels were increased in subjects with NAFLD as well as in those with visceral obesity and may be a novel biomarker for NAFLD.",
keywords = "Hepatokine, Insulin resistance, Non-alcoholic fatty liver disease, Obesity, Selenoprotein P",
author = "Choi, {Hae Yoon} and Hwang, {Soon Young} and Chang-Hee Lee and Hong, {Ho Cheol} and Yang, {Sae Jeong} and Hye-Jin Yoo and Seo, {Ji A} and Kim, {Sin Gon} and Kim, {Nan Hee} and Sei-Hyun Baik and Choi, {Dong Seop} and Choi, {Kyung Mook}",
year = "2013",
month = "2",
day = "1",
doi = "10.4093/dmj.2013.37.1.63",
language = "English",
volume = "37",
pages = "63--71",
journal = "Diabetes and Metabolism Journal",
issn = "2233-6079",
publisher = "Korean Diabetes Association",
number = "1",

}

TY - JOUR

T1 - Increased selenoprotein P levels in subjects with visceral obesity and nonalcoholic fatty liver disease

AU - Choi, Hae Yoon

AU - Hwang, Soon Young

AU - Lee, Chang-Hee

AU - Hong, Ho Cheol

AU - Yang, Sae Jeong

AU - Yoo, Hye-Jin

AU - Seo, Ji A

AU - Kim, Sin Gon

AU - Kim, Nan Hee

AU - Baik, Sei-Hyun

AU - Choi, Dong Seop

AU - Choi, Kyung Mook

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Background: Selenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP, visceral obesity, and nonalcoholic fatty liver disease (NAFLD). Methods: We examined serum SeP concentrations in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography. Our study subjects included 120 nondiabetic individuals selected from participants of the Korean Sarcopenic Obesity Study. In addition, we evaluated the relationship between SeP and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hsCRP), adiponectin values, and brachial-ankle pulse wave velocity (baPWV). Results: Subjects with NAFLD showed increased levels of HOMA-IR, hsCRP, VFA, and several components of metabolic syndrome and decreased levels of adiponectin and high density lipoprotein cholesterol than those of controls. Serum SeP levels were positively correlated with VFA, hsCRP, and baPWV and negatively correlated with the liver attenuation index. Not only subjects with visceral obesity but also those with NAFLD exhibited significantly increased SeP levels (P<0.001). In multiple logistic regression analysis, the subjects in the highest SeP tertile showed a higher risk for NAFLD than those in the lowest SeP tertile, even after adjusting for potential confounding factors (odds ratio, 7.48; 95% confidence interval, 1.72 to 32.60; P=0.007). Conclusion: Circulating SeP levels were increased in subjects with NAFLD as well as in those with visceral obesity and may be a novel biomarker for NAFLD.

AB - Background: Selenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP, visceral obesity, and nonalcoholic fatty liver disease (NAFLD). Methods: We examined serum SeP concentrations in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography. Our study subjects included 120 nondiabetic individuals selected from participants of the Korean Sarcopenic Obesity Study. In addition, we evaluated the relationship between SeP and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hsCRP), adiponectin values, and brachial-ankle pulse wave velocity (baPWV). Results: Subjects with NAFLD showed increased levels of HOMA-IR, hsCRP, VFA, and several components of metabolic syndrome and decreased levels of adiponectin and high density lipoprotein cholesterol than those of controls. Serum SeP levels were positively correlated with VFA, hsCRP, and baPWV and negatively correlated with the liver attenuation index. Not only subjects with visceral obesity but also those with NAFLD exhibited significantly increased SeP levels (P<0.001). In multiple logistic regression analysis, the subjects in the highest SeP tertile showed a higher risk for NAFLD than those in the lowest SeP tertile, even after adjusting for potential confounding factors (odds ratio, 7.48; 95% confidence interval, 1.72 to 32.60; P=0.007). Conclusion: Circulating SeP levels were increased in subjects with NAFLD as well as in those with visceral obesity and may be a novel biomarker for NAFLD.

KW - Hepatokine

KW - Insulin resistance

KW - Non-alcoholic fatty liver disease

KW - Obesity

KW - Selenoprotein P

UR - http://www.scopus.com/inward/record.url?scp=84874952628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874952628&partnerID=8YFLogxK

U2 - 10.4093/dmj.2013.37.1.63

DO - 10.4093/dmj.2013.37.1.63

M3 - Article

VL - 37

SP - 63

EP - 71

JO - Diabetes and Metabolism Journal

JF - Diabetes and Metabolism Journal

SN - 2233-6079

IS - 1

ER -